Medtronic Is Separating Its Diabetes Business

Medtronic (MDT) plans to spin off its Diabetes business, representing 8% or $2.75B of FY25 revenue, into a separate publicly traded company via a two-step transaction. The move aims to allow Medtronic to focus on higher-margin, faster-growing segments like pulsed field ablation, while the Diabetes unit, growing 10.7% Y/Y in FY25, will gain operational autonomy to enhance R&D and commercial efforts; analysts estimate the standalone Diabetes company could be valued between $8 billion and $11 billion, and the streamlined Medtronic may see a re-rating and 100 bps margin expansion.

Analysis

Medtronic plc has announced a strategic separation of its Diabetes business, which accounted for $2.75 billion or 8% of its FY2025 revenue, into an independent, publicly traded entity named "SpinCo". This separation, anticipated to conclude within 18 months, will be executed as a tax-free, two-step transaction involving an initial minority IPO carve-out followed by a full split-off. The primary driver for this restructuring is Medtronic's strategic pivot towards higher-margin and faster-growing segments, such as pulsed field ablation and renal denervation. The Diabetes unit, despite a recent 10.7% year-over-year revenue growth in FY2025, has historically underperformed its peers like Dexcom, Abbott, and Tandem Diabetes Care, and operates on a predominantly B2C model, contrasting with Medtronic's core B2B focus, thus offering limited synergies. Post-separation, SpinCo is expected to gain operational autonomy to bolster R&D and commercial activities. GSBR Research estimates SpinCo's valuation could range between $8 billion and $11 billion, potentially trading at a 3-4x price-to-sales multiple. The remaining Medtronic, with nearly $31 billion in FY2025 revenue ex-Diabetes, is projected to benefit from an enhanced focus on high-margin growth markets, potentially leading to a 100 basis point expansion in operating margins and a re-rating of its shares as investors recognize its streamlined operational profile.

Key Decisions for Investors

• Investors should assess the potential for value creation in Medtronic (MDT) shares as the company streamlines its portfolio to focus on higher-margin growth areas, which is anticipated to expand operating margins by approximately 100 basis points.
• Consider the forthcoming Diabetes "SpinCo" as a distinct investment opportunity, given its recent 10.7% year-over-year growth and estimated valuation of $8-$11 billion, while factoring in the competitive pressures from established players like DXCM, ABT, and TNDM.
• Monitor the execution progress of the tax-free separation over the next 18 months and the subsequent financial performance of both entities, particularly SpinCo's ability to leverage its autonomy for innovation and Medtronic's success in its targeted high-growth markets.